Brain tumor immunotherapy with type-1 polarizing strategies.

  title={Brain tumor immunotherapy with type-1 polarizing strategies.},
  author={Hideho Okada},
  journal={Annals of the New York Academy of Sciences},
Although the safety of vaccine approaches for central nervous system (CNS) malignancies has been established in early phase clinical trials, the success of a vaccine strategy will depend critically on the ability of effector T cells to home in to CNS tumors and durably exert antitumor effects. Based on our recent studies, efficient CNS tumor homing is a characteristic of cytotoxic T lymphocytes (CTLs) with a type 1 phenotype (Tc1), and this appears to be related to the Tc1 response to the type… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 23 extracted citations


Publications referenced by this paper.
Showing 1-10 of 45 references

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

  • N Butowski
  • J. Neurooncol
  • 2009

Toll like receptor-3 ligand polyICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

  • X Zhu
  • J. Transl. Med
  • 2007

Similar Papers

Loading similar papers…